Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

Description

Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF) or diastolic heart failure. In this single center diagnostic study, we will evaluate for ATTR in patients with HFpEF in order to to determine how frequently this occurs and how we can predict which heart failure patients may have TTR amyloidosis. Our goal is to identify amyloidosis in heart failure patients earlier so that they can start treatment.

Conditions

Transthyretin Amyloidosis, Heart Failure, Heart Failure, Diastolic, Amyloidosis

Talk to us

Study Overview

On this page

Study Details

Study overview

Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF) or diastolic heart failure. In this single center diagnostic study, we will evaluate for ATTR in patients with HFpEF in order to to determine how frequently this occurs and how we can predict which heart failure patients may have TTR amyloidosis. Our goal is to identify amyloidosis in heart failure patients earlier so that they can start treatment.

Prevalence and Prediction of Transthyretin Amyloidosis in Ambulatory Patients With Heart Failure With Preserved Ejection Fraction

Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

Condition
Transthyretin Amyloidosis
Intervention / Treatment

-

Contacts and Locations

Boston

Massachusetts General Hospital, Boston, Massachusetts, United States, 02114

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients with a confirmed diagnosis of HFpEF.
  • * Age ≥65 years old
  • * End stage chronic kidney disease on dialysis (CKD stage 5 as defined as eGFR \<15mL/min)
  • * no history of HFrEF (LVEF\<40%) with the exception of low LVEF in the setting of acute decompensation, AF RVR, ACS/MI, etc
  • * Negative 99mTc-pyrophosphate scan within a year
  • * Unable to lie down for 15 minutes for the 99mTc-pyrophosphate scan
  • * Known diagnosis of amyloidosis
  • * Severe valvular heart disease that is uncorrected (moderate to severe is considered exclusionary)

Ages Eligible for Study

65 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Massachusetts General Hospital,

Hanna K Gaggin, MD, PRINCIPAL_INVESTIGATOR, Massachusetts General Hospital

Study Record Dates

2024-12-31